Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin superfamily member 21 (IGSF21) is a GPI-anchored membrane protein containing two (or three, depending on isoform) immunoglobulin-like domains and is part of the immunoglobulin superfamily. It is specifically expressed in the brain on the postsynaptic membrane and acts as a synaptic adhesion molecule that interacts with presynaptic neurexin2α, facilitating the selective differentiation and organization of inhibitory (GABAergic) synapses, especially in the hippocampus and cortex. Knockout mouse studies show that IGSF21 is essential for proper inhibitory synaptic transmission and that its absence leads to deficits in CNS inhibitory networks and sensorimotor gating. IGSF21 is not currently associated with any therapeutic drugs or direct biomarker applications, but its biological role makes it relevant to the fundamental understanding of inhibitory synapse regulation in the central nervous system.
Not applicable; there are no drugs or small molecules reported to modulate IGSF21, so no drug mechanisms of action are described.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin superfamily member 21 (IGSF21).